ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...
Stocktwits on MSN
IBRX garners retail attention on positive update in immunotherapy for lung cancer patients
The company said that responding patients lived longer overall, with a median survival of 16.2 months. ・The data come from ...
ImmunityBio, Inc. ( IBRX) 44th Annual J.P. Morgan Healthcare Conference January 11, 2026 7:00 PM EST ...
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...
Blood eosinophil count at a specific threshold shows high sensitivity and specificity for diagnosing eosinophilic ...
ImmunityBio (IBRX) announced results from its Anktiva clinical program in non-small cell lung cancer based on two studies, ...
ANKTIVA, in combination with an immune checkpoint inhibitor, has received accelerated approval from the Saudi Food and Drug ...
Every time our body encounters a new disease-causing agent, a crucial defense system called adaptive immunity comes into play ...
Cervical lymphadenopathy presents a shared anatomic challenge for clinicians, yet it serves as the divergent starting point ...
VO2 max is an intimidating word for an easy-to-understand biometric: It’s how well your body uses oxygen when you push ...
Abrar's interests include phones, streaming, autonomous vehicles, internet trends, entertainment, pop culture and digital accessibility. In addition to her current role, she's worked for CNET's video, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback